Eisai Company, Limited

Hayashibara Biochemical Laboratories, Inc.

Toshiji Igarashi

Isao Yamatsu

Yoshikage Nakajima

Yuichi Inai

Shinya Abe

Shizumasa Kijima

Hideaki Watanabe

Yoshio Tanabe

Hiroyuki Shiojiri

Norio Minami

Shinichi Kitamura

Kimio Hamamura

Youji Yamagishi

Sachiyuki Hamano

Yuithi Inai

Kuniko Hara

Kumiko Hara

Satoru Tanaka

Hachiro Sugimoto

Koichiro Ueda

Takaharu Nakamura

Yoshiharu Daiku

Mikihiko Yoshida

Noboru Yanaihara

Shinzaburo Ohtake

Sachiyuki Hamazo

Youichi Kunii

Kunji Naito

Keiichi Nomura

Masayuki Mathukura

A quinazoline compound having the below shown formula or a pharmaceutically acceptable salt thereof is useful for treatment and prevention of ischemic cardiac disease or arrhythmia. ##STR1## in which R is a lower alkyl, methoxy, a halogen, phenyl, a phenyl substituted with methanesulfonyl, furyl, styryl or a styryl substituted with a halogen, methoxy or methylenedioxy.

Treating and preventing agent for ischemic cardiac disease and arrhythmia

1-Substituted-spiro[chroman-4,4'-imidazolidine]-2',5'-dione compounds are useful for treating arrhythmia.

Antiarrhythmic

This invention relates to polyprenylcarboxylic acid amides represented by the following general formula (I): ##STR1## wherein n is an integer of from 1 to 4, a and b stand for hydrogen atoms or a direct valence bond between the carbon atoms to which a and b are attached, c and d stand for hydrogen atoms or a direct valence bond between the carbon atoms to which c and d are attached, and R.sub.1 and R.sub.2 stand for a hydrogen atom, a lower alkyl group, a phenyl group which may be substituted or an aralkyl group which may be substituted, or R.sub.1 and R.sub.2 form, together with the adjacent nitrogen atom, a 5- or 6-membered heterocyclic ring which may contain other hetero atoms or may be substituted, and also to a process for the preparation of said polyprenylcarboxylic acid amide and to a pharmaceutical composition for treating liver dysfunction comprising said polyprenylcarboxylic acid amide.

Polyprenylcarboxylic acid morpholides and pharmaceutical compositions

An .alpha.,.beta.-dihydropolyprenyl derivative having the formula (I): ##STR1## wherein X represents a group of --COOR.sub.1 or --CH.sub.2 OR.sub.2 in which R.sub.1 is the hydrogen atom or an alkyl group having one to four carbon atoms and R.sub.2 is the hydrogen atom or an aliphatic acyl group having one to four carbon atoms; and n is an integer of one to four. A process for the preparation of the .alpha.,.beta.-dihydropolyprenyl derivative and a therapeutic agent for treatment of liver diseases comprising the same are also disclosed.

.alpha.,.beta.-Dihydropolyprenyl derivatives for treating hepatitis

An .alpha.,.beta.-dihydropolyprenyl derivative having the formula (I): ##STR1## wherein X represents a group of --COOR.sub.1 or --CH.sub.2 OR.sub.2 in which R.sub.1 is the hydrogen atom or a lower alkyl group and R.sub.2 is the hydrogen atom or an aliphatic acyl group having one to four carbon atoms; and n is an integer of one to four. A process for the preparation of the .alpha.,.beta.-dihydropolyprenyl derivative and a therapeutic agent for treatment of liver diseases comprising the same are also disclosed.

.alpha.,.beta.-Dihydropolyprenyl derivatives useful in treating hepatitis

Polyprenyl carboxylic acid amides of the formula ##STR1## process for their preparation and use thereof for treating liver dysfunction are disclosed.

Polyprenylcarboxylic acid amides useful for treating liver dysfunction

A novel compound has the following formula: ##STR1## in which R.sub.1 and R.sub.2 are methyl or a group having the formula: ##STR2## provided that one of R.sub.1 and R.sub.2 is methyl and the other is said group, wherein R stands for a hydrogen atom or a lower alkyl group, Z stands for a group ##STR3## in which X.sub.1 and X.sub.2, which may be the same or different, stand for a hydrogen atom, a lower alkyl group, a lower alkoxy group, a trifluoromethyl group or a halogen atom, or a pyridyl group or a group ##STR4## in which Y.sub.1 and Y.sub.2, which may be the same or different stand for a hydrogen atom, a lower alkyl group, a lower alkoxy group, a trifluoromethyl group or a halogen atom, X stands for a nitrogen or carbon atom, and n is an integer of from 2 to 10, provided that when R.sub.2 is the group having the formula II, X is not carbon and Z is not pyridyl.

Theophylline and theobromine derivatives

Derivatives of 2-substituted-cyclohexane-1,3-diones possessing antihypertensive activity.

Cyclohexane derivatives, process for preparation thereof and medicines

Novel plasma expander which consists of a refined pullulan having a narrow molecular weight distribution falling within the range of from 30,000 to 90,000; preparation of said plasma expander in a form suitable for intravenous injection in surgical operation and prevention of hemorrhage; and isolation of said refined pullulan from the conventional pullulan which possesses the molecular weight distribution broader than that mentioned above.

Plasma expander

.beta., .gamma.-Dihydropolyprenyl alcohols of the general formula: ##STR1## wherein n represents an integer of 8 to 10, exhibit hypotensive activity and anti-hepatic disease-activity.

.beta., .gamma.-Dihydropolyprenyl alcohol and hypotensive pharmaceutical

This invention relates to a hypertension treating agent comprising an ester of a polyprenyl alcohol of the general formula: ##STR1## wherein n represents an integer of 7-10 and R' is a saturated or unsaturated aliphatic hydrocarbon group of 1-17 carbon atoms; cyclohexyl group; unsubstituted phenyl group or phenyl group substituted with a halogen atom or a lower alkoxy group; (halogen atom-substituted phenoxy)-lower alkyl group; or pyridyl group.

Method of treating hypertension with polyprenyl alcohol ester

This invention relates to a hypertension treating agent comprising a polyprenyl alcohol or an ester thereof of the general formula: ##STR1## wherein n represents an integer of 7-10 and A represents a group of the general formula: ##STR2## in which a and b each represent hydrogen or they may form a bond, or ##STR3## in which R represents hydrogen or --COR', R' being a saturated or unsaturated aliphatic hydrocarbon group of 1-17 carbon atoms; cyclohexyl group; unsubstituted phenyl group or phenyl group substituted with a halogen atom or a lower alkoxy group; (halogen atom-substituted phenoxy)-lower alkyl group; or pyridyl group.

Hypertension treating agent containing polyprenyl alcohol

A polyprenyl carboxylic acid compound represented by the following general formula: ##STR1## wherein R stands for a hydrogen atom or an alkyl, alkenyl, cycloalkyl or aryl group, and n is an integer of 6 to 11. This compound is effective to treat hypertension of warm blooded animals.

Polyprenyl carboxylic acid compound and hypotensive agent containing it

Hypertension can be treated with a nicotinate of chroman of the formula: ##STR1## WHEREIN N IS AN INTEGER OF FROM 0 TO 3, R.sub.1 stands for ##STR2## and R.sub.2 stands for --CH.sub.3 or ##STR3## with the proviso that when R.sub.1 is ##STR4## R.sub.2 is --CH.sub.3 and the case where both of R.sub.1 and R.sub.2 stand for --CH.sub.3 is excluded.

Growing community of inventors

Tokorozawa, Japan

Toshiji Igarashi